Evidence-based safety information about medication, vaccine, chemical and radiological exposures in pregnancy

Treatment of COVID-19 in pregnancy

Read our monograph on COVID-19 treatments in pregnancy for the most up-to-date information on COVID-19 treatment.

COVID-19 Antivirals Pregnancy Registry

We are gathering information about the use of COVID-19 antivirals in pregnancy (UKHSA/MHRA collaboration). Please report into our registry.

Treatment and prophylaxis of monkeypox

Latest UKTIS advice on monkeypox.

Monkeypox infection, vaccination and treatments for pregnant women.

Recent updates to the Lyrica SmPC

UKTIS, as part of ENTIS, have submitted an official communication to the EMA Pharmacovigilance and Risk Assessment Committee (PRAC) to highlight their concerns with recent updates to the Lyrica SmPC (read the letter here).

We have also published a critical appraisal of published studies investigating malformation risks following maternal pregabalin use in pregnancy in the British Journal of Clinical Pharmacology (read the full article here)

Live vaccines in infants exposed to infliximab

Guidance has been provided from a number of authorities around avoiding/deferring live vaccine use in infants exposed to infliximab in utero.

A case-by-case assessment is required, taking into consideration likely concentration of infliximab and the clinical need for vaccination.

High-dose folic acid in WWE and cancer risk

In response to the results of a large multi-national study investigating cancer risks in the offspring of women with epilepsy who used high-dose folic acid in pregnancy we have prepared a position statement providing our interpretation of the evidence. High-dose folic acid use in women with epilepsy in pregnancy and childhood cancer risk – UKTIS.

Link to the study – Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy

Latest papers from the field of teratology

Study provides data on childhood infection risk following in utero anti-TNFα monoclonal antibody exposure

Report published on the prevalence and trends of fetal malformation in the Alberta Congenital Anomalies Surveillance System, 1997 to 2019

Large population-based study suggests no increased major malformation risk following maternal first trimester atomoxetine use

Maternal and perinatal outcomes following pre-Delta, Delta, and Omicron SARS-CoV-2 variants infection among unvaccinated pregnant women

No increased risk of ADHD following benzodiazepine/z-drug hypnotic use in pregnancy

Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US

UKTIS on Twitter

Who are UKTIS?

UKTIS is commissioned by the UK Health Security Agency (UKHSA) and hosted by The Newcastle upon Tyne Hospitals NHS Foundation Trust to perform national surveillance of known and emerging human teratogens.

Information collected by UKTIS is recognised by the Caldicott Advisory Panel of UKHSA.